

Client: Example Client ABC123 123 Test Drive

Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB Unknown
Gender: Unknown

Patient Identifiers: 01234567890ABCD, 012345

Visit Number (FIN): 01234567890ABCD **Collection Date:** 00/00/0000 00:00

CYP₂B6

ARUP test code 3004310

2B6 Specimen

Whole Blood

CYP2B6 Genotype

*1/*1

CYP2B6 Phenotype

Normal

2B6 Interpretation

See Note

The following CYP2B6 alleles were detected: *1/*1. This result predicts the normal metabolizer phenotype.

Recommendation: Guidelines for genotype-based dosing are published by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and can be found at: https://cpicpgx.org/ and https://www.pharmgkb.org/.

This result has been reviewed and approved by ■

 \mathbb{H} =High, L=Low, *=Abnormal, C=Critical

4848



BACKGROUND INFORMATION FOR CYP2B6: CHARACTERISTICS: The cytochrome P450 (CYP) isozyme 2B6 is involved in the metabolism of many drugs. Variants in the gene that codes for CYP2B6 may influence pharmacokinetics of substrates and may predict or explain non-standard dose requirements, therapeutic failure, or adverse reactions. Inheritance: Autosomal codominant CAUSE: CYP2B6 gene variants affect enzyme function. VARIANTS TESTED: (Variants are numbered according to the following transcripts:

*1: Indicative of no detected targeted variants and an assumption of functional allele.

CYP2B6 NM_000767).

CYP2B6*4: rs2279343, c.785A>G CYP2B6*6: rs3745274, c.516G>T; rs2279343, c.785A>G CYP2B6*7: rs3745274, c.516G>T; rs2279343, c.785A>G; rs3211371, c.1459C>T CYP2B6*9: rs3745274, c.516G>T CYP2B6*18: rs28399499, c.983T>C CYP2B6*22: rs34223104, c.-82T>C CYP2B6*36: rs34223104, c.-82T>C; rs3745274, c.516G>T; rs2279343, c.785A>G

CLINICAL SENSITVITY: Drug-dependent.
METHODOLOGY: Polymerase chain reaction (PCR) and fluorescence
monitoring

ANALYTICAL SENSITIVITY AND SPECIFICITY: Greater than 99 percent LIMITATIONS: Only the targeted CYP2B6 variants will be detected by this test, and assumptions about phase and content are made to assign alleles. Publicly available sources such as the www.pharmvar.org or www.pharmgkb.org provide guidance on phenotype predictions and allele frequencies. Diagnostic errors can occur due to rare sequence variations. Risk of therapeutic failure or adverse reactions with CYP2B6 substrates may be affected by genetic and non-genetic factors that are not detected by this test. This result does not replace the need for therapeutic drug or clinical monitoring.

Please note the information contained in this report does not contain medication recommendations and should not be interpreted as recommending any specific medications. Any dosage adjustments or other changes to medications should be evaluated in consultation with a medical provider. This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

EER CYP2B6

See Note

Authorized individuals can access the ARUP Enhanced Report using the following link:

 \mathbb{H} =High, L=Low, *=Abnormal, C=Critical



VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
2B6 Specimen	23-324-114879	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CYP2B6 Genotype	23-324-114879	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CYP2B6 Phenotype	23-324-114879	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
2B6 Interpretation	23-324-114879	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
EER CYP2B6	23-324-114879	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical